Santhera Pharmaceuticals, the licensor of AGAMREE, announced it secured approximately CHF 20 million in additional funding from existing investors Highbridge and R-Bridge. This funding is specifically designated to accelerate the global rollout of AGAMREE (vamorolone).
The company reported that demand for AGAMREE in the U.S. and China is ahead of plan, leading to increased inventory needs and shifts in launch timing. This strong demand for AGAMREE is a positive indicator for Catalyst Pharmaceuticals, which holds the North American commercial rights for the Duchenne muscular dystrophy treatment.
The accelerated global rollout and higher-than-expected demand for AGAMREE by its licensor suggest continued strong performance and market penetration for the product. This development supports Catalyst's revenue projections and its strategic focus on AGAMREE as a key growth driver.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.